Abstract
The Metabolic Syndrome is a common metabolic disease associated with an increased risk for atherosclerotic cardiovascular disease and mortality. In contrast to “traditional” risk factors for atherosclerosis, such as low-density lipoprotein cholesterol, the Metabolic Syndrome represents a network of interacting risk factors stemming from the metabolic complexity of this disease. For this reason, dissection of the cellular and molecular pathways underlying atherosclerosissusceptibility in the Metabolic Syndrome has been difficult. To facilitate this endeavor, several murine models have been recently developed. Despite their imperfect representation of the Metabolic Syndrome and atherosclerosis in humans, these models have provided important mechanistic insights and revealed novel molecular pathways. Furthermore, murine models are invaluable for the evaluation of therapeutic approaches and will no doubt facilitate the genetic dissection of atherosclerosis-susceptibility in the Metabolic Syndrome.
Keywords: triglycerides clearance, cardiovascular disease, VLDL secretion, JNK activity, hyperglycemia
Current Drug Targets
Title: Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Volume: 8 Issue: 11
Author(s): Miklos Peterfy, Richard C. Davis and Aldons J. Lusis
Affiliation:
Keywords: triglycerides clearance, cardiovascular disease, VLDL secretion, JNK activity, hyperglycemia
Abstract: The Metabolic Syndrome is a common metabolic disease associated with an increased risk for atherosclerotic cardiovascular disease and mortality. In contrast to “traditional” risk factors for atherosclerosis, such as low-density lipoprotein cholesterol, the Metabolic Syndrome represents a network of interacting risk factors stemming from the metabolic complexity of this disease. For this reason, dissection of the cellular and molecular pathways underlying atherosclerosissusceptibility in the Metabolic Syndrome has been difficult. To facilitate this endeavor, several murine models have been recently developed. Despite their imperfect representation of the Metabolic Syndrome and atherosclerosis in humans, these models have provided important mechanistic insights and revealed novel molecular pathways. Furthermore, murine models are invaluable for the evaluation of therapeutic approaches and will no doubt facilitate the genetic dissection of atherosclerosis-susceptibility in the Metabolic Syndrome.
Export Options
About this article
Cite this article as:
Peterfy Miklos, Davis C. Richard and Lusis J. Aldons, Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models, Current Drug Targets 2007; 8 (11) . https://dx.doi.org/10.2174/138945007782403838
DOI https://dx.doi.org/10.2174/138945007782403838 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Granular Non-Fibrillar Aggregates and Toxicity in Alzheimer’s Disease
Current Alzheimer Research Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
Current Cardiology Reviews Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry Gene Therapy in Disorders of Lipoprotein Metabolism
Current Gene Therapy In Silico Classification and Prediction of VIP Derivatives as VPAC1/ VPAC2 Receptor Agonists/Antagonists
Combinatorial Chemistry & High Throughput Screening Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets In-Silico QSAR Modelling of Predicted Rho Kinase Inhibitors Against Cardio Vascular Diseases
Current Computer-Aided Drug Design Premature Aging in Fibromyalgia
Current Aging Science Roles of CLR/RAMP Receptor Signaling in Reproduction and Development
Current Protein & Peptide Science Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology